Abiopharma

🔍 Yarema Kristin (Executive)

Company: ImageneBio, Inc. (IMA)

Report Date: 2026-08-14

Detailed Transactions and Holdings:

• Acquired 254,800 shares of Common Stock (Direct)
  Date: 2026-08-14 | Code: A | equity_swap_involved: 0 | shares_owned_after: 493,705.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 137,200 shares of Employee Stock Option (right to buy) at $5.84 per share (Derivative)
  Date: 2026-08-14 | Code: A | Expires: 2036-08-13 | equity_swap_involved: 0 | shares_owned_after: 137,200.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 250,000 shares of Employee Stock Option (Right to Buy) at $5.84 per share (Derivative)
  Date: 2026-08-14 | Code: A | Expires: 2036-08-13 | equity_swap_involved: 0 | shares_owned_after: 250,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents the number of shares of the Issuer's Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on April 14, 2027, and the remaing RSUs will vest in a series of 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
• F2: The options vest over four years, with 25% of the shares vesting on April 14, 2027, and the remaining shares vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
• F3: The options vest over four years in a series of 48 successive equal monthly installments commencing on May 14, 2026, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.